Twin Tree Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12M | Sell |
24,500
-9,500
| -28% | -$5.16M | 0.25% | 62 |
|
|
2025
Q4 | $19.7M | Buy |
34,000
+18,100
| +114% | +$10.2M | 0.17% | 136 |
|
|
2025
Q3 | $7.71M | Sell |
15,900
-12,900
| -45% | -$6M | 0.03% | 597 |
|
|
2025
Q2 | $11.7M | Sell |
28,800
-222,800
| -89% | -$93.2M | 0.02% | 713 |
|
|
2025
Q1 | $125M | Buy |
+251,600
| New | +$136M | 0.24% | 56 |
|
|
2023
Q2 | – | Sell |
-18,800
| Closed | -$10.8M | – | 1510 |
|
|
2023
Q1 | $10.8M | Sell |
18,800
-23,700
| -56% | -$13.4M | 0.02% | 558 |
|
|
2022
Q4 | $23.4M | Buy |
42,500
+12,100
| +40% | +$6.41M | 0.05% | 359 |
|
|
2022
Q3 | $15.4M | Buy |
+30,400
| New | +$17M | 0.03% | 436 |
|
|
2022
Q2 | – | Sell |
-30,000
| Closed | -$17.7M | – | 1842 |
|
|
2022
Q1 | $17.7M | Sell |
30,000
-19,600
| -40% | -$11.3M | 0.03% | 514 |
|
|
2021
Q4 | $33.1M | Buy |
49,600
+14,700
| +42% | +$9.18M | 0.07% | 263 |
|
|
2021
Q3 | $19.9M | Sell |
34,900
-239,400
| -87% | -$131M | 0.04% | 364 |
|
|
2021
Q2 | $138M | Buy |
274,300
+31,000
| +13% | +$14.6M | 0.37% | 38 |
|
|
2021
Q1 | $111M | Buy |
243,300
+220,700
| +977% | +$105M | 0.41% | 45 |
|
|
2020
Q4 | $10.5M | Sell |
22,600
-25,100
| -53% | -$11.8M | 0.04% | 430 |
|
|
2020
Q3 | $21.1M | Sell |
47,700
-150,900
| -76% | -$62.3M | 0.09% | 252 |
|
|
2020
Q2 | $72M | Buy |
198,600
+116,500
| +142% | +$39M | 0.29% | 60 |
|
|
2020
Q1 | $23.3M | Sell |
82,100
-30,800
| -27% | -$9.71M | 0.11% | 166 |
|
|
2019
Q4 | $36.7M | Buy |
112,900
+108,300
| +2,354% | +$32.8M | 0.13% | 135 |
|
|
2019
Q3 | $1.34M | Buy |
+4,600
| New | +$1.32M | 0.01% | 769 |
|
|
2019
Q1 | – | Sell |
-2,600
| Closed | -$582K | – | 1600 |
|
|
2018
Q4 | $582K | Sell |
2,600
-16,100
| -86% | -$3.78M | ﹤0.01% | 950 |
|
|
2018
Q3 | $4.56M | Sell |
18,700
-79,500
| -81% | -$18.3M | 0.03% | 413 |
|
|
2018
Q2 | $20.3M | Buy |
+98,200
| New | +$20.8M | 0.12% | 137 |
|
|
2017
Q1 | – | Sell |
-37,700
| Closed | -$5.32M | – | 1256 |
|
|
2016
Q4 | $5.32M | Sell |
37,700
-136,500
| -78% | -$20.1M | 0.05% | 383 |
|
|
2016
Q3 | $27.7M | Buy |
174,200
+148,900
| +589% | +$22.9M | 0.35% | 46 |
|
|
2016
Q2 | $3.74M | Buy |
25,300
+9,100
| +56% | +$1.34M | 0.06% | 327 |
|
|
2016
Q1 | $2.29M | Sell |
16,200
-17,500
| -52% | -$2.35M | 0.04% | 387 |
|
|
2015
Q4 | $4.78M | Buy |
33,700
+29,500
| +702% | +$3.93M | 0.09% | 208 |
|
|
2015
Q3 | $514K | Buy |
+4,200
| New | +$547K | 0.01% | 776 |
|
|
2014
Q4 | – | Sell |
-9,100
| Closed | -$1.11M | – | 1193 |
|
|
2014
Q3 | $1.11M | Buy |
+9,100
| New | +$1.11M | 0.03% | 550 |
|
|
2014
Q2 | – | Sell |
-9,600
| Closed | -$1.15M | – | 1022 |
|
|
2014
Q1 | $1.15M | Buy |
9,600
+7,100
| +284% | +$844K | 0.02% | 588 |
|
|
2013
Q4 | $278K | Buy |
2,500
+2,300
| +1,150% | +$229K | 0.01% | 803 |
|
|
2013
Q3 | $18K | Sell |
200
-44,300
| -100% | -$4.01M | ﹤0.01% | 781 |
|
|
2013
Q2 | $3.77M | Buy |
+44,500
| New | +$3.7M | 0.15% | 153 |
|
Other funds holding TMO
VCM
Twin Tree Management's TMO Position: Q4 2025 in Review
Twin Tree Management sold out of Thermo Fisher Scientific (TMO) in Q4 2025, closing a stake of 59,013 shares — an estimated $33.4M sold.
Twin Tree Management first reported a position in TMO in Q4 2013 and held it in 21 quarters. The position peaked at $39.1M in Q3 2022. 2,699 funds tracked by Wall St. Rank hold TMO as of Q4 2025.
- Twin Tree Management reported no remaining Thermo Fisher Scientific position as of Q4 2025 after selling out during the quarter.
- Twin Tree Management sold 59,013 Thermo Fisher Scientific shares in Q4 2025, an estimated $33.4M.
- Twin Tree Management first reported a position in Thermo Fisher Scientific in Q4 2013 and held it in 21 quarters.
- Twin Tree Management's Thermo Fisher Scientific position peaked at $39.1M in Q3 2022.
- 2,699 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2025.
Based on Twin Tree Management's 13F filing for Q4 2025, filed 11 Feb 2026.